(Q24200361)

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

A double-blind pilot study of risperidone in the treatment of conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Olanzapine treatment in adolescents with severe conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

A clinical case series of six extremely aggressive youths treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

The Nisonger CBRF: a child behavior rating form for children with developmental disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Psychopharmacologic control of aggression and violence in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Aripiprazole for autism spectrum disorders (ASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

An epidemiological study of disorders in late childhood and adolescence--I. Age- and gender-specific prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Ten-Year Review of Rating Scales. VI: Scales Assessing Externalizing Behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Show me the child at seven: the consequences of conduct problems in childhood for psychosocial functioning in adulthood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Review of safety assessment methods used in pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Reliability, validity, and preliminary normative data for the Children's Aggression Scale-Teacher Version

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

A meta-analytic review of components associated with parent training program effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Parent management training: evidence, outcomes, and issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Treatment of aggressive children with clonidine: results of an open pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Multisystemic Therapy for social, emotional, and behavioral problems in youth aged 10-17

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Functional Family Therapy for families of youth (age 11-18) with behaviour problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Males on the life-course-persistent and adolescence-limited antisocial pathways: follow-up at age 26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Ten-year review of rating scales. I: overview of scale functioning, psychometric properties, and selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Controversies concerning the diagnosis and treatment of bipolar disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. American Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

The Nisonger Child Behavior Rating Form: age and gender effects and norms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Pharmacological aspects of the treatment of conduct disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Reactive aggression in boys with disruptive behavior disorders: behavior, physiology, and affect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

The Overt Aggression Scale for the objective rating of verbal and physical aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

Psychopharmacologic strategies for the treatment of aggression in juveniles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Infant and toddler pathways leading to early externalizing disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Development, reliability, and validity of the children's aggression scale-parent version

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Profiles of aggression among psychiatric patients. I. Nature and prevalence.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Early conduct problems and later life opportunities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

Evidence for Interventions for Young Offenders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008559.PUB2

7 January 2021

10.1002/14651858.CD008559.PUB2

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pggp4vhw6bgw5nn56dubk3byem

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_pggp4vhw6bgw5nn56dubk3byem

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pggp4vhw6bgw5nn56dubk3byem

30 July 2022

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

3423522

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3423522

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/pggp4vhw6bgw5nn56dubk3byem

30 July 2022